ALK and non-small cell lung carcinoma: This study was a multicenter, real-world retrospective study involving stage III unresectable NSCLC patients carrying mutations in EGFR/ALK/ROS genes, recruited from the Jinling Hospital and the Jiangsu Cancer Hospital in Nanjing, Jiangsu Province.